A widely publicized press release and subsequent preliminary report of the RECOVERY trial, a randomized study conducted in the UK, noted a survival benefit with the use of dexamethasone in hospitalized patients with coronavirus disease 2019 (COVID-19). 1 The use of dexamethasone for management of COVID-19 has already increased, particularly given the recent National Institutes of Health COVID-19 Treatment Panel guidelines that recommend its use. 2 Although clinicians are familiar with the most common adverse effects associated with dexamethasone, a corticosteroid, they may be less familiar with a potentially severe, but preventable, less common complication: Strongyloides hyperinfection or dissemination syndrome (hyperinfection). 3 Strongyloidiasisiscausedbyanematode(roundworm) infection, with most human disease associated with Strongyloidesstercoralis.Strongyloidesinfectionispredominantly acquired through contact with soil contaminated withfree-livinglarvae,whichpenetratetheskinandmigrate totheintestine,wheretheylayeggs.Eggsareexcretedinto the environment where they hatch. Larvae complete the lifecyclebypenetratingtheskinofanewhost.Unlikeother soil-transmittedinfections,eggsofStrongyloidesmayhatch into filariform larvae in the intestines and directly autoinoculate, reinfecting their human host (autoinfection) withoutanenvironmentalstage.Thisuniquecharacteristicperpetuates chronic infection, often lasting for decades.Although a majority of individuals with strongyloidiasis are asymptomatic, a severe disease manifestation is hyperinfection syndrome. This frequently fatal iatrogenic complication is usually associated with use of an immunosuppressive drug in persons with unrecognized chronic infection. The most common precipitator is use of a corticosteroid agent, which appears to be independent of dose or duration of treatment. [3][4][5] Coinfection with human T-lymphotropic virus type 1, which is disproportionately found in immigrant and refugee populations, is also associated with hyperinfection syndrome. 3,4 Although prevalence data are lacking from many regionsoftheworld,Strongyloidesisestimatedtoinfecthundreds of millions of people worldwide, 3,6 with studies sug-gestingthat10%to40%ofpopulationsintropicalandsubtropical regions may be infected. 6,7 A 2019 meta-analysis of studies involving migrants worldwide found a pooled strongyloidiasis seroprevalence of 12.2%; the prevalence was 17.3% among migrants from Asia, 14.6% among migrants from sub-Saharan Africa, and 11.4% among those from Latin America and the Caribbean. 8 The prevalence among certain populations of refugees from Africa and Asia arriving in the US is estimated to approach 50%. 9 Although there are no incidence or prevalence estimates